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Abstract 
Background: Global malaria control efforts are threatened by the spread and emergence of artemisinin-resistant 
Plasmodium falciparum parasites. In 2012, the widespread sale of partial courses of artemisinin-based monotherapy 
was suspected to take place in the highly accessed, weakly regulated private sector in Myanmar, posing potentially 
major threats to drug resistance. This study investigated the presence of artemisinin-based monotherapies in the 
Myanmar private sector, particularly as partial courses of therapy, to inform the targeting of future interventions to 
stop artemisinin resistance.
Methods: A large cross-sectional survey comprised of a screening questionnaire was conducted across 26 town-
ships in Myanmar between March and May, 2012. For outlets that stocked anti-malarials at the time of survey, a stock 
audit was conducted, and for outlets that stocked anti-malarials within 3 months of the survey, a provider survey was 
conducted.
Results: A total of 3,658 outlets were screened, 83% were retailers (pharmacies, itinerant drug vendors and general 
retailers) and 17% were healthcare providers (private facilities and health workers). Of the 3,658 outlets screened, 
1,359 outlets (32%) stocked at least one anti-malarial at the time of study. Oral artemisinin-based monotherapy com-
prised of 33% of self-reported anti-malarials dispensing volumes found. The vast majority of artemisinin-based mono-
therapy was sold by retailers, where 63% confirmed that they sold partial courses of therapy by cutting blister packets. 
Very few retailers (5%) had malaria rapid diagnostic tests available, and quality-assured artemisinin-based combination 
therapy was virtually nonexistent among retailers.
Conclusion: Informal private pharmacies, itinerant drug vendors and general retailers should be targeted for inter-
ventions to improve malaria treatment practices in Myanmar, particularly those that threaten the emergence and 
spread of artemisinin resistance.
Keywords: Malaria, Artemisinin-based monotherapy, Drug resistance, ACTwatch, Private sector, Myanmar
© 2015 Khin et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
*Correspondence:  Ingrid.chen@ucsf.edu 
2 Global Health Sciences, University of California, San Francisco, 550 16th 
Street, 3rd Floor, San Francisco, CA 94158, USA
Full list of author information is available at the end of the article
Page 2 of 9Khin et al. Malar J  (2015) 14:269 
Background
In Southeast Asia, drug resistance of Plasmodium fal-
ciparum parasites against first-line anti-malarials, the 
artemisinins, threaten malaria control efforts worldwide. 
Much like the previous spread of chloroquine resistance, 
the first signs of artemisinin-resistant parasites were 
seen in Cambodia in 2009 [1], which have since emerged 
independently in several locations and have now spread 
to Myanmar, Cambodia, Laos, Thailand, and Vietnam 
[2–5]. Myanmar accounts for approximately 85% of the 
reported malaria cases in the Greater Mekong sub-region 
of Asia [2], and the spread of artemisinin resistance 
throughout Myanmar would be devastating not only for 
the 37 million individuals living in Myanmar’s malaria-
endemic areas, but for the global fight against malaria.
In Myanmar, malaria is a well-known problem hav-
ing been a leading cause of morbidity and mortality in 
Myanmar for over two decades [2]. Although malaria 
endemicity in Myanmar has been dropping in recent 
years, with an estimated 495,000 cases in 2013 [2], the 
spread of drug-resistant P. falciparum parasites threatens 
these gains [5]. To prevent a global health emergency, all 
practices that threaten the emergence of P. falciparum 
parasites must be changed, and all artemisinin-resistant 
parasites must be contained and eliminated [6, 7].
In Myanmar, the informal private sector has been 
implicated for practices that threaten the emergence of 
drug resistance. When this study was initiated in 2012, it 
was suspected that the most common practice in Myan-
mar was to treat symptoms of malaria with an incom-
plete course of artemisinin-based monotherapy. This 
practice was largely implicated in the emergence of drug 
resistance, which may be selected for when parasites sur-
vive low, subtherapeutic doses of drug exposures [7]. To 
prevent drug resistance against artemisinin-class drugs, 
the World Heath Organisation (WHO) recommends the 
use of artemisinin-based combination therapy (ACT) as 
a first-line treatment for P. falciparum malaria [5]. How-
ever, ACT is expensive, and when available in Myanmar, 
patients often could not afford it. In this case, providers 
were suspected to cut the blister packets of ACT, sell-
ing partial courses of artemisinin-based monotherapy 
instead [7].
In order to remove artemisinin monotherapies from 
the market in Myanmar, and to encourage the sale of 
only full courses of ACT, there was first a need deter-
mine where artemisinin-based monotherapies were sold, 
and whether they were indeed sold as partial courses of 
therapy. This study targeted the private sector, the highly 
accessed, weakly regulated, first point of care of fever 
for most individuals in Myanmar where the widespread 
sale of artemisinin-based monotherapy was suspected to 
take place [2]. The private sector is comprised of private 
clinics, pharmacies, informal drug shops, and general 
retailers, where antimalarial drugs and rapid diagnostic 
tests (RDTs) for malaria can be sold by any individual, 
without the need for certification or formal training.
This study, conducted in Myanmar in 2012, aimed 
to determine what types of private  outlets exist, what 
types of anti-malarial drugs were in stock at each outlet, 
whether RDTs for malaria were available, and whether 
providers were selling partial courses of treatment. The 
information gained from this study has since been used 
to enable a large-scale transformation of the anti-malarial 
market in Myanmar, where artemisinin-based monother-
apies have been successfully replaced with ACT [8]. This 
study should be used as an example of a baseline assess-
ment for other countries seeking to improve malaria 
treatment and diagnostic practices in the private sector.
Methods
Study area and design
The study employed a cross-sectional survey compris-
ing a full census of 3,746 outlets across 26 townships in 
Myanmar (the country contains a total of 325 townships), 
carried out between March and May 2012 (Figure  1). 
The methods used for this study were adapted from the 
ACTwatch programme [9], which recorded the types of 
private outlets sampled, outlet locations, availability of 
various anti-malarials among outlets sampled, provider 
demographics, and a brief assessment of provider knowl-
edge and practices for malaria treatment.
Sampling approach
A cluster sampling approach was adopted using a two-
stage probability proportion to size (PPS) cluster design, 
with the measure of size being the relative cluster popu-
lation. Clusters were defined as geographical areas, such 
as wards in urban areas and village tracts in rural areas. 
Sampling frames of all townships were developed after 
excluding 51 townships that were inaccessible for secu-
rity reasons and/or inaccessibility.
At the first stage of sampling, 26 townships across 
Myanmar were selected using PPS. The number of town-
ships included was based on operational feasibility. In 
each selected township, the sampling frame consisted of 
wards (which are the smallest administrative geographic 
unit to represent an urban area) and village tracts. At 
the second stage of sampling, a total of 122 wards and 
130 village tracts were selected using PPS. Each selected 
township had at least four wards and five village tracts. 
For each township, five wards and five village tracts were 
selected using PPS unless the selected township had only 
four wards, in which case all four wards were selected. 
Within the selected ward or village tract, a census of all 
outlets in the private sector that could potentially sell or 
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provide anti-malarials to individuals was conducted using 
a snowball sampling approach. Population Services Inter-
national (PSI) field staff members started either from the 
highway bus terminal or from market places and walked 
to nearby general stores or drug shops, asking individu-
als working in shops whether they knew of other places in 
the ward or village selling or providing anti-malarial treat-
ments. Maps were used to help to identify cluster bounda-
ries and the areas that PSI field staff members would visit. 
Each provider interviewed would also be asked to identify 
other outlets providing anti-malarial treatments in the 
area.
A total of 3,746 outlets were identified (Figure  1a), 
and key informants were available in 3,658 of these out-
lets (Figure 1b). Of these 3,658 outlets, key informants in 
1,359 outlets reported that they stocked anti-malarials 
within 3 months of the survey date (Figure 1c), were asked 
to participate in the provider module, and 1,274 outlets 
participated [85 outlets (6%) declined to participate] (Fig-
ure  1d). Of these 1,274 outlets, 1,159 key informants in 
outlets reported that that they stocked anti-malarials on 
the day of the survey visit, all of whom participated in a 
full anti-malarial drug audit  (Figure  1e). The analysis of 
anti-malarial stocks and provider knowledge in this report 
is based on these 1,159 outlets.
Inclusion criteria
An outlet was defined as any point of sale or provision 
of commodities for individuals. Two types of outlets were 
sampled; healthcare providers and retailers. Healthcare 
providers were comprised of privately owned hospitals 
or clinics tended by general practitioners (which may or 
may not be affiliated with a franchise network), as well as 
community health workers providing treatment outside 
of the public health facilities. Retailers were comprised 
of registered pharmacies, itinerant drug vendors (hawk-
ers), and general retailers such as village stores, grocer-
ies, and general stores. In Myanmar, registration with 
the City Development Committee is required to open a 
pharmacy, also called a ‘drug shop’, and defined as any 
outlet that mainly sells drugs. However, as regulation and 
enforcement are weak in Myanmar, many pharmacies in 
rural areas like the ones studied herein do not seek regis-
tration. The majority of itinerant drug vendors are mobile 
drug vendors that serve people within a catchment area 
of approximately five or six villages within their area of 
residence. Most itinerant drug vendors received train-
ing from previous jobs (e.g. assistant to an army nurse, 
a nurse aid at a private hospital, or a clinical assistant 
to a medical doctor) and provide services in the same 
place for many years, and are therefore well-known by 
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Figure 1 Selection process for outlet inclusion.
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the population, and easy to find and identify. For all out-
lets included, a key informant, defined as the owner of 
the shop, provider or pharmacist working at the shop, 
needed to be available at the time of survey. All key 
informants were required to be at least 18  years of age, 
and willing to provide informed verbal consent to partici-
pate in the study.
Data collection instruments
The outlet questionnaire was comprised of three mod-
ules: (1) a screening module for all outlets included; (2) 
a provider module for all outlets that reported to stock 
anti-malarials in the past 3  months; and (3) an audit 
module for outlets with anti-malarials in stock on the day 
of interview.
The screening module was used to record the type and 
location of all outlets, and to identify outlets in which to 
conduct the provider module, and the audit module. The 
provider module was used to collect descriptive informa-
tion on providers, including basic demographics such as 
the level of education and type of formal health training 
received by all employees at the outlet, as reported by the 
provider interviewed. This module also asked provid-
ers whether they could name different types of malaria 
(P. falciparum vs Plasmodium vivax malaria), whether 
they knew the government recommended treatment 
for uncomplicated P. falciparum malaria (the use of the 
ACT artemether–lumefantrine), and whether they ever 
cut blister packs, or sold partial courses of anti-malarials 
over the past month, as well as their reasons for doing so.
The audit module was based on standard methods 
developed and tested by the WHO Health Action Inter-
national questionnaire for essential medicines [10]. For 
each anti-malarial drug in stock, the interviewer asked 
to see the drugs, and recorded information on the brand 
and generic names, drug strength, package size, country 
of origin, and expiration date (from anti-malarial packag-
ing). The interviewer then asked the provider to recall the 
price to the customer, and the amount sold in the last week 
(from records where available). Artemisinin-based mono-
therapy was defined as an anti-malarial medicine that has 
a single active compound called artemisinin or one of its 
derivatives, including artesunate and artemether. Non-
artemisinin therapy included chloroquine, quinine and pri-
maquine, which is recommended for the treatment of vivax 
malaria. Drugs intended solely for malaria chemoprophy-
laxis were not included in this study. The audit module also 
collected information on whether malaria rapid diagnostic 
test (RDTs) were in stock on the day of the interview.
Data collection procedures
Paper questionnaires were administered during data 
collection. The questionnaire was finalized in English 
and translated and administered in local Myanmar 
language versions. All staff involved in the study, 
including the data collection team, underwent a 6-day 
training on how to identify anti-malarial medicines, 
including the differences between ACT and non-ACT, 
brands and generic names, drug packaging, and drug 
strength. The training addressed the purpose of the 
study, the importance of consent, and how to admin-
ister the consent form and study questionnaires. The 
study received ethical approval from the PSI Research 
Ethics Board.
Data analysis
To allow for meaningful comparisons between anti-
malarials with different treatment courses, the vol-
ume of anti-malarials recorded in the audit module was 
standardized using the adult equivalent treatment dose 
(AETD). One AETD was defined as the amount of the 
drug, in milligrams, that a 60  kg adult would need in 
order to receive a full course of treatment according to 
the availability of information according to the follow-
ing three sources of information, in order of priority: 
(1) the WHO; (2) peer reviewed literature; or (3) from 
manufacturer guidelines. The provider-reported num-
ber of packages distributed was scaled to the equivalent 
number of AETD courses sold in the previous week. For 
combination anti-malarials, one drug in the combination 
was selected for these calculations. For ACT, this was 
always the artemisinin-derivative component (e.g., the 
artemether component of artemether–lumefantrine).
For the purpose of this study, anti-malarials were 
analyzed as three policy-relevant categories: ACT, 
artemisinin-based monotherapy, and non-artemisinin 
therapy. ACT was sub-divided into quality assured ACT 
(QA-ACT), defined as an ACT pre-qualified by WHO 
and/or authorized for marketing by a Stringent Drug 
Regulatory Authority [11], and non-quality assured ACT 
(non QA-ACT), defined as any ACT not included in the 
WHO prequalification list. Artemisinin-based mono-
therapy was sub-categorized into oral artemisinin-based 
monotherapy, a contributing factor for drug resistance 
malaria [2], and injectable artemisinin-based monother-
apy, the recommended drug for severe malaria in hospital 
settings [12].
In order to test for statistically significant differences 
between healthcare providers and retailers (at the 0.05 
level), t tests were used for continuous variables, and Chi 
square tests for categorical variables.
To ensure data quality, two-pass verification, also 
known as double data entry was conducted using a data-
base system designed with in-built checks for consist-
ency and range values. Data analysis was conducted in 
Stata 11.0 (Stata Corp College Station, TX, USA), which 
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included descriptive summaries across different outlet 
types. Sampling weights based on the cluster population 
size used allow for the provision of national estimates.
Results
Outlet screening
Of the 3,658 outlets screened, 83% were retailers and 
17% were healthcare providers  (Table 1). A total of 46% 
of the outlets were located in urban areas, and 54% were 
in rural areas. In urban areas, private facilities (88%) and 
pharmacies (86%) were the most commonly found drug 
providers, while in rural areas, health workers (79%) and 
itinerant drug vendors (80%) were the most commonly 
found drug providers. General retailers were more evenly 
distributed between rural and urban areas, with 60% 
being located in rural areas and 40% in urban areas.
A total of 1,159 outlets screened (32%) stocked at least 
one anti-malarial at the time of study (Table  1). Anti-
malarial availability was highest in pharmacies (76%), 
followed by private facilities (69%) and health work-
ers (67%), and lowest among general retailers (12%), the 
most common outlet type screened (2,297 outlets, 63%).
Stock audit module
Among outlets that had anti-malarials on the day of the 
survey, 58% of outlets stocked oral artemisinin-based 
monotherapy, and 24% stocked QA-ACT (Table 2). QA-
ACT was available in 60% of treatment professional 
Table 1 Demographics of private sector outlets screened
* Comparing healthcare providers to retailers.










N (%) 3,658 283 (8%) 324 (9%) 607 (17%) 450 (12%) 304 (8%) 2,297 (63%) 3,051 (83%)
Location
 Urban 1,684 (46%) 249 (88%) 68 (21%) 317 (51%) 387 (86%) 61 (20%) 919 (40%) 1,367 (45%) <0.05
 Rural 1,974 (54%) 34 (12%) 256 (79%) 290 (49%) 63 (14%) 243 (80%) 1,378 (60%) 1,684 (55%)
Stocking any  
anti-malarial at 
time of survey
1,159 (32%) 194 (69%) 218 (67%) 412 (68%) 342 (76%) 136 (45%) 269 (12%) 747 (24%) <0.001
Table 2 Availability of anti-malarial drugs and malaria rapid diagnostic tests in private outlets
Among those outlets that had any anti-malarials in stock on the day of visit.
** Comparing healthcare providers to retailers.
† Columns do not always add up to 100% because one outlet can stock more than one type of anti-malarial drug; percentages are column percent.










N (%) 1,159 194 (17%) 218 (19%) 412 (36%) 342 (29%) 136 (12%) 269 (23%) 747 (64%)
Availability of anti-malarial
 Quality assured 
ACT†
280 (24%) 93 (48%) 156 (72%) 249 (60%) 10 (3%) 11 (8%) 10 (4%) 31 (4%) <0.001
 Non-artemisinin 
drugs








677 (58%) 83 (43%) 44 (20%) 127 (31%) 304 (89%) 39 (29%) 207 (77%) 550 (74%) <0.001
 Non QA-ACT 67 (6%) 24 (12%) 2 (1%) 26 (6%) 38 (11%) 1 (1%) 2 (1%) 41 (6%) <0.05
Availability of  
RDT
293 (25%) 99 (51%) 157 (72%) 256 (62%) 20 (6%) 12 (9%) 5 (2%) 37 (5%) <0.001
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outlets, and 4% of retailer outlets (p  <  0.001). Among 
retailers, QA-ACT was lowest among pharmacies (3%) 
and general retailers (4%). Artemisinin-based mono-
therapies were present in 74% of retailer outlets with 
the highest percentages seen among pharmacies (89%) 
and general retailers (77%), as compared to only 3% of 
treatment professional facilities (p  <  0.001). The pres-
ence of injectable artemisinin monotherapies was similar 
between healthcare providers and retailer outlets (33 and 
28%, respectively). The availability of non-artemisinin 
drugs was highest among itinerant drug vendors (83%), 
and otherwise similar across all other outlet types (49–
64%). RDTs were available in 62% of treatment profes-
sional outlets, and only 5% of retailers outlets (p < 0.001), 
with lowest rates (2%) among general retailers.
Estimates of anti-malarials volumes sold within the 
past 7  days showed the highest rate of sales for non-
artemisinin drugs (38.1%), followed by oral artemisinin-
based monotherapy (32.9%) and QA-ACT (21.7%) 
(Figure 2). Analysis across different outlet types showed 
that pharmacies were the most significant contributor 
of oral artemisinin-based monotherapies. QA-ACT was 
virtually non-existent among all retailers, but was widely 
available among healthcare providers.
Provider module
Among outlets surveyed, 55% were staffed by university 
graduates, 38% by high school graduates, and 7% having 
completed primary school as their highest level of educa-
tion (Table 3). The attainment of a University degree was 
higher among healthcare providers (73%) than retailers 
(45%, p < 0.001), with highest levels seen among private 
facilities (99%) and lowest levels seen among itinerant 
drug vendors (19%).
Formal health training among outlets surveyed showed 
that 16% of outlets were operated or staffed by medical 
doctors, 20% by nurse or midwives, 2% by health assis-
tants, and 3% by pharmacists, with much higher rates of 
formal training among healthcare providers (43% were 
medical doctors and 33% were nurses/midwives) than 
retailers (1% were medical doctors and 12% were nurses/
midwives, p < 0.001).
A brief assessment of provider knowledge of malaria 
revealed that 45% of providers could name P. falciparum 
and P. vivax as different types of malaria, and only 20% 
of providers were aware that artemether–lumefantrine 
was the recommended first-line treatment of malaria 
(Table  3). Within these individuals, correctly answered 
questions were higher among healthcare providers than 
retailers (for types of malaria, 87 vs 31%, p  <  0.001, for 
the first-line treatment of malaria, 50 vs 4%, p  < 0.001), 
with lowest levels observed among general retailers (20% 
for types of malaria, and 2% for first-line treatment).
A total of 46% of the 1,159 outlets that stocked anti-
malarial drug(s) at the time of survey reported that they 
cut blister packets and/or sold partial courses of anti-
malarial treatments to patients (Table  2). This practice 
was reported by 63% of retailers and 15% of healthcare 
providers (p  <  0.001), with highest rates reported by 
general retailers (77%). The most common reason that 
providers stated for cutting blister packets was due to 
customer request (68%), and the second most common 
Figure 2 Relative volume of anti-malarial drugs sold in the previous 7 days by outlet type in Myanmar.
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reason was that customers could not afford a full blister 
or pack of treatment (25%). Other reasons also included 
that providers stated that cutting a blister packet made it 
easier for patients to take medicine (17%), or that cutting 
blister packets provided sufficient treatment to patients 
(15%).
Discussion
This study was the first to investigate the private sector 
anti-malarial market in Myanmar on a large scale, exam-
ining the availability of anti-malarial drugs and malaria 
RDTs in private outlets, the types of anti-malarial drugs 
available in various types of outlets, provider demograph-
ics and basic knowledge of types of malaria and treat-
ment guidelines for falciparum malaria, and provider 
practices pertaining to the cutting of blister packets and/
or the same of partial courses of anti-malarial drugs.
This study confirmed that oral artemisinin-based mon-
otherapy was indeed widely available in the Myanmar 
private sector, and furthermore showed that within the 
private sector, retailers should take priority in receiving 
interventions designed to improve malaria treatment and 
diagnosis practices. The presence of oral artemisinin-
based monotherapy was much higher among retail-
ers (74%) than healthcare providers (31%), and retailers 
reported higher rates of cutting blister packs (63%) than 
healthcare providers (15%). Education levels and provider 
knowledge on the types of malaria and treatment guide-
lines for falciparum malaria were also much lower among 
retailers compared to healthcare providers (45 vs 73% 
university graduates, 31 vs 76% named types of malaria 
correctly, and 4 vs 52% knew the first-line treatment for 
falciparum malaria, respectively). QA-ACT was also vir-
tually non-existent among retailers (4%), but found in 
60% of healthcare provider outlets.
These results suggest two types of interventions to 
improve malaria treatment and diagnostic practices 
within the private sector. The first is the targeting of 
retailers to replace the sale of oral artemisinin-based 
monotherapy with QA-ACT. This could minimize prac-
tices suspected to contribute to the development of arte-
misinin resistance, as QA-ACT contains a long-acting 
partner drug designed to clear remaining malaria para-
sites when levels of short-acting artemisinin-class drugs 
are in the body. Since under-dosing of artemisinin-class 
can contribute to the emergence of drug resistance, the 
replacement of QA-ACT with oral artemisinin-based 
monotherapy can minimize risks that parasites develop 
artemisinin resistance [7]. Since QA-ACT have higher 
costs than oral artemisinin-based monotherapy [13], sell-
ing them at a subsidized cost is expected to be necessary 
for intervention effectiveness [7].
The second type of intervention is to provide educa-
tion to providers, once again targeting retailers, who 
Table 3 Provider attributes and blister-cutting practices in private sector outlets stocking anti-malarials
* Comparing healthcare providers to retailers.
† Columns do not always add up to 100% because multiple responses are possible.










N (%) 1,159 194 (17%) 218 (19%) 412 (36%) 342 (29%) 136 (12%) 269 (23%) 747 (64%)
Education
 Primary 81 (7%) 0 (0%) 4 (2%) 4 (1%) 4 (1%) 16 (12%) 57 (21%) 77 (10%) <0.001
 High school 446 (38%) 2 (1%) 107 (49%) 109 (26%) 96 (28%) 94 (69%) 147 (55%) 337 (45%) <0.001
 Graduate 632 (55%) 192 (99%) 107 (49%) 299 (73%) 242 (71%) 26 (19%) 65 (24%) 333 (45%) <0.001
Type of health provider†
 Medical doctor 185 (16%) 178 (92%) 0 (0%) 178 (43%) 7 (2%) 0 (0%) 0 (0%) 7 (1%) <0.001
 Nurse/midwife 229 (20%) 21 (11%) 122 (56%) 143 (35%) 52 (15%) 26 (19%) 8 (3%) 86 (12%) <0.001
 Health assistant 26 (2%) 2 (1%) 20 (9%) 22 (5%) 3 (1%) 1 (1%) 0 (0%) 4 (1%)  < 0.05
 Pharmacist 35 (3%) 5 (3%) 2 (1%) 7 (2%) 24 (7%) 1 (1%) 3 (1%) 28 (4%) <0.001
 Knows types of 
malaria
523 (45%) 97 (50%) 192 (88%) 289 (87%) 116 (34%) 64 (47%) 54 (20%) 234 (31%) <0.001




233 (20%) 95 (49%) 113 (52%) 208 (50%) 14 (4%) 11 (8%) 5 (2%) 30 (4%) <0.001
 Provider prac-
tice: do cut 
the blisters
531 (46%) 19 (10%) 43 (20%) 62 (15%) 205 (60%) 57 (42%) 207 (77%) 469 (63%) <0.000
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had lower levels of education than healthcare providers, 
and cut blister packets more often. Education should be 
focused on improved malaria treatment, including the 
use of QA-ACT as per treatment guidelines for falci-
parum malaria, as well as the dangers of cutting blister 
packets in case it should lead to under-dosing, and hence 
increased risks of drug resistance. This study did not 
assess whether drugs were dispensed at accurate doses, 
and did not assess whether providers knew of proper 
dosing guidelines, so future studies or educational inter-
ventions should ensure that providers are indeed aware 
of proper dosing practices. Furthermore, it should also 
be emphasized that while retailers should be prioritize 
for interventions, healthcare providers showed lim-
ited knowledge on the first-line treatment of falciparum 
malaria (50%), and could also therefore benefit from 
interventions.
The presence of injectable artemisinin-based mono-
therapies in private outlets (33% among healthcare pro-
viders, 28% among retailers) could also warrant further 
investigation, because injectable artesuate is recom-
mended for the treatment of severe malaria [12]. Future 
studies can investigate whether individuals with severe 
malaria indeed present in private facilities, and if so, 
whether providers are able to provide proper care for 
severe malaria, an assessment which should include the 
ability of providers to administer injections, and whether 
they have access to clean needles and are able to safely 
dispose of used ones.
After this study took place, the two interventions sug-
gested above were indeed carried out, to successfully 
replace oral artemisinin-based monotherapies with sub-
sidized QA-ACT [8], and then to ensure their proper use 
through the use of subsidized RDTs [14–16]. Interest-
ingly, educational campaigns to both the provider and 
the community proved to be effective, with increased 
educational visits to providers leading to increased lev-
els of RDT use [14–16]. This follow-up intervention also 
offered the potential to crowd out the supply of sub-
standard and counterfeit ACT, offering a relatively simple 
solution to an otherwise challenging problem [7].
This study offers methods that can be used by other 
countries seeking to transform malaria diagnosis and 
treatment practices in the private sector. Indeed, ACT-
Watch methods have been used in several countries 
in Africa [8, 17], and Cambodia has also undertaken a 
nationwide landscaping study on the availability of anti-
malarials within the private sector [18]. This type of 
large-scale cross sectional study provides baseline infor-
mation on what kind of providers exist in the private sec-
tor, what types of drugs they stock, and which types of 
interventions are likely to improve the quality of the care 
offered. A number of factors must be considered in local 
contexts, both with regard to interpreting results, and 
navigating future interventions. The successful follow-up 
intervention to this study in Myanmar is partially attrib-
uted to the ease of permeating the supply chain, as Myan-
mar providers rely on a highly centralized supply chain 
offered by the AA pharmacy. The broader notion how-
ever, that the private sector can be engaged with ACT 
subsidies, is entirely transferable as long as the actual 
strategies used follow local cultural contexts.
Limitations
The study also did not access public facilities in Myan-
mar and therefore did not provide the landscape of the 
overall anti-malarial market in areas studied. Although 
the size of the study allowed for the provision of national 
estimates, it is possible that this study was not nationally 
representative, as townships excluded for security reasons 
may have different accessibility to anti-malarial drugs. 
Snowball sampling, the method used to identify private 
providers in this study, has inherent limitations includ-
ing that the researcher relies mainly on previous subjects 
observes such that there is potential for sampling bias as 
participants are more likely to nominate someone who has 
similar characteristics to themselves. As a result of these 
potential biases, the representativeness of the sample is 
not guaranteed, as the researcher cannot be sure that they 
have indeed obtained a true distribution of private provid-
ers throughout the population. The volumes of anti-malar-
ials documented in this study were also self-reported by 
providers, and therefore subject to recall biases, as well as 
a potential desire for a shopkeeper to tell the interviewer 
what they wanted to hear. The study also did not account 
for all potential risk factors contributing to the selection 
for drug resistance (e.g. patient adherence to antimalarial 
drugs). The study did not assess the actual dispensing of 
drugs and the accuracy of doses dispensed, so the provider 
reporting of cutting blister packets does not necessarily 
imply under-dosing. Finally, although practices implicated 
in the spread of artemisinin drug resistance were identi-
fied, there was no proven causal relationship.
Conclusion
Oral artemisinin-based monotherapy was most com-
monly found among general retailers in rural settings, 
and these providers commonly cut blister packs when 
selling anti-malarials to patients. As a result of this study, 
general retailers were targeted for a large-scale inter-
vention to replace artemisinin-based monotherapy with 
subsidized QA-ACT throughout the Myanmar private 
sector. This study should be used as an example of a base-
line assessment to improve malaria treatment practices 
in Myanmar in locations where the private sector is a 
common first point of care for fever.
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